TSLP and breast carcinoma: Indeed, IL-1 was shown to be a key factor for activation of TSLP secretion in both pancreatic (22) and breast cancer (21), where the use of the IL-1R antagonist anakinra reduced TSLP availability in vitro and in vivo.